Search Results - "Viero, M L"

The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state by Patrassi, G M, Sartori, M T, Viero, M L, Scarano, L, Boscaro, M, Girolami, A

“…The aim of our study was to determine the fibrinolytic potential in a large group of patients with Cushing's disease. These patients had a significant…”
Get more information

Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor by Patrassi, G M, Sartori, M T, Casonato, A, Viero, M L, Pontara, E, Saggiorato, G, Girolami, A

“…Nine healthy volunteers and 23 patients with various types of von Willebrand disease were studied before and after DDAVP infusion. We investigated the…”
Get more information

DDAVP effect on factor XII activity levels by Patrassi, G M, Sartori, M T, Viero, M L, Santarossa, A, Casonato, A, Girolami, A

Get more information

Venous thrombosis and tissue plasminogen activator release deficiency: a family study by Patrassi, G M, Sartori, M T, Viero, M L, Boscaro, M, Boeri, G, Girolami, A

“…Thrombotic events are often due to fibrinolytic defects such as impaired tissue plasminogen activator (tPA) synthesis and/or release or increased plasminogen…”
Get more information

Fibrinolytic effects of defibrotide in atherosclerotic patients by Patrassi, G M, Sartori, M T, Viero, M L, Scapinello, M P, Boeri, G, Girolami, A

“…Defibrotide is a polydeoxyribonucleotide salt that shows antithrombotic activity through a suggested profibrinolytic mechanism. To study the effectiveness of…”
Get more information

Factor XII activation after DDAVP by Patrassi, G M, Sartori, M T, Lazzaro, A R, Viero, M L, Boscaro, M, Girolami, A

Get more information

Bait contracts by Viero, M.-L.

“…This article explores contracting in the presence of ambiguity. It revisits Holmström's sufficient statistic result of when to condition a contract on an…”
Get full text

Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus : relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy by DORIA, A, GHIRARDELLO, A, BOSCARO, M, VIERO, M. L, VACCARO, E, PATRASSI, G. M, GAMBARI, P. F

“…Endothelial cell damage in systemic lupus erythematosus (SLE) was evaluated by measuring fibrinolytic activity and von Willebrand factor levels. Tissue-type…”
Get full text

Laser nephelometer evaluation of factor IX by Ruzza, G, Lazzaro, A R, Viero, M L, Girolami, A

“…Laser Nephelometry is a technique which allows the evaluation of the concentration of several serum proteins and clotting factors. By means of this technique…”
Get more information

Fibrinolytic effect of a particular glycosaminoglycan (endoglycan) per os on normals and in patients with chronic artery disease by Patrassi, G M, Veronesi, A, Sartori, M T, Viero, M L, Boeri, G, Girolami, A

“…Endoglycan, a heparan-dermatan sulphate association, is a highly purified heparinoid extracted from porcine intestinal mucosa. The aim of our study was to…”
Get more information

Emprego da RT-PCR em tempo real para a quantificaÇão da expressão de genes associados à resposta imune em bezerros bovinos experimentalmente infectados por Neospora caninum by Nishi, S. M., Viero, L. M., Soares, R. M., Maiorka, P. C., Gennari, S. M.

“…Neospora caninum é um dos principais agentes causadores de abortamentos e natimortalidade em bovinos. A defesa imune do hospedeiro é capaz de inibir a…”
Get full text

Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus: Relationhip with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy by Doria, A., Ghirardello, A., Boscaro, M., Viero, M. L., Vaccaro, E., Patrassi, G. M., Gambari, P. F.

Get full text